Skip to main content
Fig. 3 | BMC Neurology

Fig. 3

From: Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab

Fig. 3

Change from baseline in MIDAS item scores measuring absenteeism* and presenteeism† over 2 years. MIDAS, Migraine Disability Assessment. *Absenteeism comprises the average of Items 1, 3, and 5. Item 1: missed work/school; Item 3: no household work; Item 5: missed family/social/leisure activities. The average at baseline was 9.7 †Presenteeism comprises the average of Items 2 and 4. Item 2: work/school productivity ≤ half; Item 4: household productivity ≤ half. The average at baseline was 14.2

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us